| Outcome Measures: |
Primary: Primary efficacy index :hemoglobin concentration, the amount of change in mean Hb concentration compared with baseline Hb concentration during the evaluation period (25th-32nd week), 25th-32nd week | Secondary: Secondary efficacy index:maintenance rate, the proportion of subjects whose average Hb concentration remained within the target range during the evaluation period, 25th-32nd week|Secondary efficacy index :proportion of subjects, the proportion of subjects whose range of dose adjustments decreased or increased by 25% still did not reach 100-120 g/L (both ends), for 32 weeks|Secondary efficacy index: proportion of times, the proportion of times the measured Hb concentration remains within the target range during the subject evaluation period, 25th-32nd week|Secondary efficacy index : average weekly dose, the average weekly dose of the drug during the evaluation period (normalized by body weight), 25th-32nd week|Secondary efficacy index: EPO dose conversion coefficient of rESP, the EPO dose conversion coefficient of rESP (the average weekly dose of rESP during the screening period) and the dose correlation, for 32 weeks|Secondary efficacy index : mean reticulocyte count, changes in mean values of reticulocyte compared to baseline values during the evaluation period., 25th-32nd week|Secondary efficacy index : mean red blood cell count, changes in mean values of red blood cell count compared to baseline values during the evaluation period, 25th-32nd week|Safety indicator: adverse events, the type, proportion and severity of adverse events, for 32 weeks|Safety indicator: number of dose adjustments, the number of dose adjustments used by the subject during the treatment and evaluation period, for 32 weeks|Safety indicator: the ratio of subjects who are adjusted, the ratio of subjects who are adjusted during the treatment and evaluation period, for 32 weeks|Safety indicator: incidence of erythropoietin (EPO) antibodies and anti-rESP antibodies, incidence of erythropoietin (EPO) antibodies and anti-rESP antibodies, for 32 weeks|Maximum Plasma Concentration (Cmax), the Cmax of rESP in patients with long-term medication., for 32 weeks|Area Under the Curve (AUC), the AUC of rESP in patients with long-term medication., for 32 weeks
|
